75 related articles for article (PubMed ID: 9367887)
21. Ethanol-induced neuronal apoptosis in vivo requires BAX in the developing mouse brain.
Young C; Klocke BJ; Tenkova T; Choi J; Labruyere J; Qin YQ; Holtzman DM; Roth KA; Olney JW
Cell Death Differ; 2003 Oct; 10(10):1148-55. PubMed ID: 14502238
[TBL] [Abstract][Full Text] [Related]
22. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
23. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control.
Koziorowski D; Friedman A; Arosio P; Santambrogio P; Dziewulska D
Parkinsonism Relat Disord; 2007 May; 13(4):214-8. PubMed ID: 17275395
[TBL] [Abstract][Full Text] [Related]
24. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
Fernandez A; de Ceballos ML; Rose S; Jenner P; Marsden CD
Brain; 1996 Jun; 119 ( Pt 3)():823-30. PubMed ID: 8673494
[TBL] [Abstract][Full Text] [Related]
25. Presymptomatic Parkinson's disease: the Arizona experience.
Caviness JN
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S203-6. PubMed ID: 22166435
[TBL] [Abstract][Full Text] [Related]
26. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease.
Orimo S; Takahashi A; Uchihara T; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain Pathol; 2007 Jan; 17(1):24-30. PubMed ID: 17493034
[TBL] [Abstract][Full Text] [Related]
27. Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease.
Hartmann A; Mouatt-Prigent A; Vila M; Abbas N; Perier C; Faucheux BA; Vyas S; Hirsch EC
Neurobiol Dis; 2002 Jun; 10(1):28-32. PubMed ID: 12079401
[TBL] [Abstract][Full Text] [Related]
28. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.
Alam ZI; Daniel SE; Lees AJ; Marsden DC; Jenner P; Halliwell B
J Neurochem; 1997 Sep; 69(3):1326-9. PubMed ID: 9282961
[TBL] [Abstract][Full Text] [Related]
29. Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease.
Frigerio R; Fujishiro H; Maraganore DM; Klos KJ; DelleDonne A; Heckman MG; Crook JE; Josephs KA; Parisi JE; Boeve BF; Dickson DW; Ahlskog JE
Arch Neurol; 2009 Sep; 66(9):1114-9. PubMed ID: 19752300
[TBL] [Abstract][Full Text] [Related]
30. The
Wilkinson H; Thomsson KA; Rebelo AL; Hilliard M; Pandit A; Rudd PM; Karlsson NG; Saldova R
J Proteome Res; 2021 Aug; 20(8):3913-3924. PubMed ID: 34191522
[No Abstract] [Full Text] [Related]
31. Disease Duration Influences Gene Expression in Neuromelanin-Positive Cells From Parkinson's Disease Patients.
Tiklová K; Gillberg L; Volakakis N; Lundén-Miguel H; Dahl L; Serrano GE; Adler CH; Beach TG; Perlmann T
Front Mol Neurosci; 2021; 14():763777. PubMed ID: 34867188
[TBL] [Abstract][Full Text] [Related]
32. Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: neurochemical and molecular substrates.
Hayley S; Anisman H
Curr Pharm Des; 2005; 11(8):947-62. PubMed ID: 15777246
[TBL] [Abstract][Full Text] [Related]
33. Is there apoptosis in Lewy body disease?
Jellinger KA
Acta Neuropathol; 1999 Apr; 97(4):413-5. PubMed ID: 10208282
[No Abstract] [Full Text] [Related]
34. Severe early basal ganglia hypometabolism in neurodegeneration with brain iron accumulation.
Mainta IC; Tabouret-Viaud C; Horvath J; Vargas MI; Garibotto V
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1741-2. PubMed ID: 26993314
[No Abstract] [Full Text] [Related]
35. Molecular Mechanisms of Neurodegeneration in Parkinson's Disease.
Trempe JF; Gehring K
J Mol Biol; 2023 Jun; 435(12):168131. PubMed ID: 37120011
[No Abstract] [Full Text] [Related]
36. Bioactive nutraceuticals as G4 stabilizers: potential cancer prevention and therapy-a critical review.
Choudhury SD; Kumar P; Choudhury D
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3585-3616. PubMed ID: 38019298
[TBL] [Abstract][Full Text] [Related]
37. Manual acupuncture at the SJ5 (Waiguan) acupoint shows neuroprotective effects by regulating expression of the anti-apoptotic gene Bcl-2.
Lin D; Lin LL; Sutherland K; Cao CH
Neural Regen Res; 2016 Feb; 11(2):305-11. PubMed ID: 27073385
[TBL] [Abstract][Full Text] [Related]
38. Effect of Bcl-2 rs956572 polymorphism on age-related gray matter volume changes.
Liu ME; Huang CC; Yang AC; Tu PC; Yeh HL; Hong CJ; Chen JF; Liou YJ; Lin CP; Tsai SJ
PLoS One; 2013; 8(2):e56663. PubMed ID: 23437205
[TBL] [Abstract][Full Text] [Related]
39. Programmed cell death in Parkinson's disease.
Venderova K; Park DS
Cold Spring Harb Perspect Med; 2012 Aug; 2(8):. PubMed ID: 22908196
[TBL] [Abstract][Full Text] [Related]
40. Stabilization of G-quadruplex in the BCL2 promoter region in double-stranded DNA by invading short PNAs.
Onyshchenko MI; Gaynutdinov TI; Englund EA; Appella DH; Neumann RD; Panyutin IG
Nucleic Acids Res; 2009 Dec; 37(22):7570-80. PubMed ID: 19820116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
